Bromhexine
Based on 4 publication(s) in Google Scholar
Bromhexine is a potent expectorant. Bromhexine increase mucociliary clearance and reduces cough. Bromhexine can be used in study various respiratory diseases.
For research use only. We do not sell to patients.
- Purity : 99.59%
- CAS No.: 3572-43-8
- Formula: C14H20Br2N2
- Molecular Weight:376.13
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Bromhexine
MoreAll Antibiotic Isoforms
More
Biological Activity
Description
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 3572-43-8
-
Appearance Solid
-
Molecular Weight 376.13
-
Formula C14H20Br2N2
-
Color White to off-white
-
SMILES
BrC1=CC(Br)=CC(CN(C)C2CCCCC2)=C1N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
ALOX5 Promotes Autophagy-dependent Ferroptosis by Activating the AMPK/mTOR Pathway in Melanoma. [Abstract]2023 Jun:212:115554. PMID: 37080437 -
Int Immunopharmacol
A natural product, Piperlongumine (PL), increases tumor cells sensitivity to NK cell killing. [Abstract]2021 Jul:96:107658. PMID: 33887610 -
BMJ Open Respir Res
Respiratory syncytial virus-induced SIGLEC1 upregulation inhibits macrophage autophagy and facilitates inflammatory mediator secretion. [Abstract]2026 Apr 20;13(1):e003586. PMID: 42009498 -
FEBS Lett
Bromhexine elevates REP2 expression to stimulate secretion from human primary conjunctiva fornix epithelial cells. [Abstract]2020 Jan;594(1):153-160. PMID: 31365127
Protocols
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)